Blue Edge Capital Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Blue Edge Capital reduced its stake in Celgene Corporation by 1.66% during the most recent quarter end. The investment management company now holds a total of 14,140 shares of Celgene Corporation which is valued at $1,603,335 after selling 239 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Celgene Corporation makes up approximately 0.86% of Blue Edge Capital’s portfolio.

Other Hedge Funds, Including , Ingalls Snyder boosted its stake in CELG in the latest quarter, The investment management firm added 4,895 additional shares and now holds a total of 22,166 shares of Celgene Corporation which is valued at $2,513,403. Celgene Corporation makes up approx 0.14% of Ingalls Snyder’s portfolio.Wrapmanager Inc boosted its stake in CELG in the latest quarter, The investment management firm added 856 additional shares and now holds a total of 3,234 shares of Celgene Corporation which is valued at $366,703. Celgene Corporation makes up approx 0.15% of Wrapmanager Inc’s portfolio.Atlas Browninc. boosted its stake in CELG in the latest quarter, The investment management firm added 120 additional shares and now holds a total of 4,285 shares of Celgene Corporation which is valued at $480,734. Celgene Corporation makes up approx 0.19% of Atlas Browninc.’s portfolio. Bartlett added CELG to its portfolio by purchasing 25 company shares during the most recent quarter which is valued at $2,703.

Celgene Corporation closed down -0.19 points or -0.17% at $114.01 with 23,03,075 shares getting traded on Tuesday. Post opening the session at $114.49, the shares hit an intraday low of $113.92 and an intraday high of $115.52 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *